Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
HiberCell
company
About
HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic agents targeting adaptive stress.
- 51 - 100
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- $30M
- Industries
- Biotechnology,Health Care,Health Diagnostics,Medical
- Founded date
- Jan 1, 2019
- Number Of Employee
- 51 - 100
- Operating Status
- Active
HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.The company was founded in 2019 and is based in New York.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$158.15M
HiberCell has raised a total of
$158.15M
in funding over 2 rounds. Their latest funding was raised on
May 19, 2021 from a Debt Financing round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 19, 2021 | Debt Financing | $30M | 1 |
Hercules Capital
|
— | Detail |
| May 19, 2021 | Series B | $67.40M | 1 | — | — | Detail |
| Feb 7, 2019 | Series A | $60.75M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
HiberCell is funded by 2 investors.
Hercules Capital
and ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Debt Financing |
|
ARCH Venture Partners
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
